Radiopharm Theranostics Ltd
RAD 202
HER 2-positive solid tumours
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for RAD 202 in HER 2-positive solid tumours are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“The Company expects to complete enrolment in the second cohort in the first half of 2026.”